US2024009183A1PendingUtilityA1

Use of pyronaridine, tilorone, and quinacrine against marburg virus and other virus infections

66
Assignee: COLLABORATIONS PHARMACEUTICALS INCPriority: Nov 6, 2019Filed: Jul 10, 2023Published: Jan 11, 2024
Est. expiryNov 6, 2039(~13.3 yrs left)· nominal 20-yr term from priority
A61K 31/138A61P 31/14A61K 31/357A61K 31/4745A61P 31/16A61P 31/22A61K 31/473A61P 31/20A61K 31/517A61K 9/0019A61K 9/0043A61K 9/0053A61K 47/14A61K 47/38
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods of treating or preventing diseases caused by viral infections via the administration of pyronaridine, quinacrine, and/or tilorone are described. The viral infections can be caused by viruses such as Marburg virus (MARV), Chikungunya virus (CHIKV), norovirus, Middle East Respiratory Syndrome coronavirus (MERS-CoV), and Nipah virus.

Claims

exact text as granted — not AI-modified
1 . A method of treating or preventing a disease caused by a Marburg virus (MARV) infection in a subject in need of treatment thereof, wherein the method comprises administering to the subject an effective amount of tilorone and/or a pharmaceutically acceptable salt thereof. 
     
     
         2 - 8 . (canceled) 
     
     
         9 . The method of  claim 1 , wherein the subject is a mammal. 
     
     
         10 . The method of  claim 9 , wherein the subject is a human. 
     
     
         11 . The method of  claim 1 , wherein the administering is performed via oral administration, intranasal administration, or intravenous administration. 
     
     
         12 - 19 . (canceled) 
     
     
         20 . The method of  claim 1 , wherein the MARV infection is an infection of MARV, strain Musoke. 
     
     
         21 . The method of  claim 1 , wherein the MARV infection is an infection of MARV, strain Angola.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.